PACB

Pacific Biosciences of California, Inc. Common Stock

PACB
Closed
$1.56
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. The company focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Country

US

CEO

Mr. Christian Henry

IPO date

2010

Employees

485

ISIN

US69404D1081

Key stats

Open

$1.63

Volume

6.14M

Market cap

$500.07M

Prev. close

$1.61

Impl / hst vl

-

Open interest

$0.00

$1.52

Day’s Range

$1.65

$1.09

52W Range

$2.73

Valuation

38
Valuation score
Overvalued
P/E
-
P/S
2.91
P/B
196.92
Current ratio
5.65
Debt / Equity
155.60
ROE
-488.45%
Gross margin
34.54%
Income growth
-79.50%
FCF growth
164.60

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.51
The top 8 analysts forecasts that 12-month price may increase by 60.74%, with a low of $1.52 and a high of $3.15
$1.52
Low
$2.51
Avg
$3.15
High
Current price

Earnings

Q1 ‘26 revenue
$37.18M
Q1 ‘26 net income
-$8.28M
Revenue
Net income
Previous EPS
-$0.12
Estimate EPS
-$0.13
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply